PharmaTimes NICE is recommending the drug's use as a treatment option for adults with type 2 diabetes as dual therapy in combination with metformin, and in combination with insulin with or without other oral antidiabetic drugs . Currently in the UK, over one ...
Journal of Clinical Endocrinology and Metabolism and Histology (D.B.P.), Jeju National University School of Medicine , Jeju, Republic of Korea 690-756; Gachon University of Medicine and Science (B.-C.O.), Graduate Schools of Medicine , Lee Gil Ya Cancer and Diabetes Institute, Incheon, Republic of ...
MarketWatch (press release) Galvus� (vildagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor, a class of oral diabetes medications that enhance the body's natural ability to control blood sugar. The Galvus� (vildagliptin) safety and efficacy profile has been established in a ... and more »
SYS-CON Media (press release) NICE recommends the use of dapagliflozin as a treatment option for adults with Type 2 diabetes as dual therapy in combination with metformin, and in combination with insulin with or without other oral antidiabetic drugs .1 Currently in the UK, more than ... and more »
NASDAQ Moreover, the drug was well tolerated. We note that Galvus is approved for the treatment of type II diabetes as a monotherapy and in combination with metformin, a sulphonylurea, a thiazolidinedione or insulin, in more than 100 countries including EU ... and more »
Family Practice News Digital Network ... and showed a nonsignificant trend toward a higher risk for colorectal cancer (CRC). No association was noted between CRC and thiazolidinedione (TZD), Dr. Siddharth Singh reported at the annual Digestive Disease Week. ... There was considerable ... and more »
MarketWatch (press release) Galvus� (vildagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor, a class of oral diabetes medications that enhance the body's natural ability to control blood sugar. The Galvus� (vildagliptin) safety and efficacy profile has been established in a ... and more »
Family Practice News Digital Network ... and showed a nonsignificant trend toward a higher risk for colorectal cancer (CRC). No association was noted between CRC and thiazolidinedione (TZD), Dr. Siddharth Singh reported at the annual Digestive Disease Week. ... There was considerable ...
MarketWatch (press release) Galvus� (vildagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor, a class of oral diabetes medications that enhance the body's natural ability to control blood sugar. The Galvus� (vildagliptin) safety and efficacy profile has been established in a ... and more »
Family Practice News Digital Network ... and showed a nonsignificant trend toward a higher risk for colorectal cancer (CRC). No association was noted between CRC and thiazolidinedione (TZD), Dr. Siddharth Singh reported at the annual Digestive Disease Week. ... There was considerable ...
